Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Leases (Tables)

Leases (Tables)

9 Months Ended

Sep. 30, 2019

The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:

	Classification on the Balance Sheet	September 30, 2019
		(unaudited)
Assets
Financing lease assets	Property and equipment, net	$	998
Operating lease assets	Operating lease assets		4,212
Total lease assets		$	5,210

Liabilities
Current
Financing lease liabilities	Other accrued expenses	$	247
Operating lease liabilities	Other accrued expenses		1,367
Total current lease liabilities		$	1,614
Noncurrent
Financing lease liabilities	Other long-term liabilities		173
Operating lease liabilities	Operating lease liabilities		2,791
Total long-term lease liabilities			2,964
Total lease liabilities		$	4,578

Schedule of Maturities of Operating and Financing Lease Liabilties

The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2019:

	Operating Leases		Financing Leases
2019 (remaining)	$	412	$	90
2020		1,431		226
2021		1,258		120
2022		1,192		13
2023		344		-
Total minimum lease payments		4,637		449
Less: amount of lease payments representing effects of discounting		479		29
Present value of future minimum lease payments		4,158		420
Less: current obligations under leases		1,367		247
Long-term lease obligations	$	2,791	$	173

Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases

As of December 31, 2018, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows:

			Less than		1 to 3		3 to 5		After
	Total		1 Year		Years		Years		5 Years
Operating lease obligations	$	2,814	$	613	$	1,322	$	879	$	-